Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON36044
NL-OMON36044
Completed
Not Applicable

A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhinitics - GSK2245035 SAD study in HV and rhinitis patients

GlaxoSmithKline0 sites75 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAllergic reactionhay fever10024970

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Allergic reaction
Sponsor
GlaxoSmithKline
Enrollment
75
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •healthy male volunteers
  • •18 \- 55 years of age
  • •BMI 19 \- 29\.9 kg/m2;Part 2:
  • •male volunteers with a pollen allergy
  • •18 \- 55 years of age
  • •BMI 19 \- 29\.9 kg/m2
  • •positive RAST test for pollen allergy

Exclusion Criteria

  • •\- Suffering from: hepatitis B, cancer or HIV/AIDS
  • •\- Participation in another drug study within 3 months prior to dosing in this study
  • •\- Blood donation within 3 months prior to dosing in this study of donated more than 1\.5 liters of blood in the 10 months prior to dosing in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A randomized, double-blind, placebo controlled, four-period, cross-over study to evaluate the cognitive effects of single oral administration of roflumilast in aging-related memory impairmentmemory impairmentmild memory impairmentsub-clinical cognitive deficits
NL-OMON40236Takeda40
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma.subjects with mild asthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: Asthma
EUCTR2010-019465-28-SEGlaxoSmithKline Research & Development Ltd24
Completed
Not Applicable
DSP-2230 Capsaicin and UVB Challenge StudyPeripheral Neuropathic PainSigns and Symptoms
ISRCTN80154838Sunovion Pharmaceuticals Europe Ltd56
Completed
Not Applicable
A clinical study to evaluate the overall health benefits of the test formulation on elderly subjects.Health Condition 1: E70-E88- Metabolic disorders
CTRI/2020/10/028403ITC Life Sciences and Technology Centre
Active, not recruiting
Not Applicable
Tiotropium-bromide in cystic fibrosisCystic FibrosisMedDRA version: 14.1Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2010-019802-17-GBBoehringer Ingelheim Limited471